Today San Francisco, USA-based biotech start-up Alector announced the closing of a $133 million Series E financing and for the first time revealed its first three programs focused on Alzheimer’s disease and frontotemporal dementia (FTD).
Deerfield Management, AbbVie Ventures, Federated Kaufmann Fund, Section 32, Euclidean Capital, Foresite Capital, Lilly Asia Ventures, New Leaf Venture Partners, Perceptive Advisors, Casdin Capital, Polaris Partners, OrbiMed, MRL Ventures, GV, the Dementia Discovery Fund, Mission Bay Capital, Amgen Ventures, and others participated in the financing.
The new financing adds to a deal worth a potential $225 million that Alector signed with AbbVie (NYSE: ABBV) in October last year, that gave the latter an option to globally develop and commercialize two of Alector's drug targets, to treat Alzheimer’s disease and other neurodegenerative disorders. It also has a collaboration with USA-based therapeutic antibody developer Adimab
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze